Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 26, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity ownership changes within a specific employee retirement plan.
Material Changes
The primary material change reported is an increase in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: October 22, 2004
- Previous Holdings: 18,909,706 ADRs
- New Holdings: 18,944,032 ADRs
- Average Price: $42.20
Management Commentary and Risks
The filing notes that the Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees. No specific risks, contingencies, or unusual items regarding operations were disclosed in this text.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of the latest reporting date.
- Confirm the specific ownership stakes of Dr. J P Garnier and Dr. T Yamada relative to the fund's holdings.
- Check subsequent filings for any further changes in director interests or fund movements.